[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449028":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":37,"responsibleParty":62,"collaborators":10,"id":64,"slug":10,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Grupo Argentino de Tratamiento de la Leucemia Aguda","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adolescents and young adults Ph-negative ALL patients in first-line",null,"Adolescents and young adults patients (18-40 years old) with recent diagnosis of Ph-negative acute lymphoblastic leukemia who receive argentinian pediatric-like treatment depending on risk category.",[13],"Other: Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.","Evaluation of survival (event free survival and overall survival) and toxicities in AYA Ph-negative ALL patients treating in first line with argentinian pediatric-like protocol depending on risk category.",[9],[20,23,26],{"name":21,"affiliation":5,"role":22},"Maria Moirano, Dr.","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":5,"role":25},"Isolda Fernández, Dr.","STUDY_CHAIR",{"name":27,"affiliation":5,"role":22},"Luciana Ferrari, Dr.",[29,33],{"name":27,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","541148771000","lferrari@fundaleu.org.ar",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Paula Freigeiro","5491140470052","gatla.ar@gmail.com",[38,57],{"facility":39,"status":40,"city":41,"state":42,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Instituto Privado de Hematologia y Hemoterapia","RECRUITING","Paraná","Entre Ríos Province","Argentina","AR",{"type":46,"coordinates":47},"Point",[48,49],-60.52897,-31.73271,{"lat":49,"lon":48},[52,54],{"name":53,"role":30,"phone":10,"phoneExt":10,"email":10},"Pedro Negri Aranguren, Dr.",{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Florencia Negri Aranguren, Dr.","SUB_INVESTIGATOR",{"facility":58,"status":40,"city":59,"state":10,"zip":10,"country":43,"countryCode":44,"cosmosGeoPoint":10,"geoPoint":10,"contacts":60},"FUNDALEU","CABA",[61],{"name":27,"role":30,"phone":31,"phoneExt":10,"email":32},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100449028",false,"NCT05127148","RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL","Real-world Evidence of First-line Treatment With Pediatric-like Protocol for Adolescents and Young Adults Patients Diagnosed With Philadelphia-negative Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Signature of the form consent for participation in the study\n* Ph-negative ALL diagnosis without previous treatment.\n\nExclusion Criteria:\n\n* ALL with mature B phenotype (sIg +) or with the cytogenetic alterations characteristic of ALL mature B (t (8,14), t (2, 8), t (8, 22)).\n* Ph-positive ALL\n* Acute leukemias of ambiguous lineage (undifferentiated or mixed phenotype).\n* Patients with a history of coronary, valvular or hypertensive heart disease, that contraindicate the use of anthracyclines.\n* Patients with chronic liver disease in the activity phase and \u002F or Bilirubin\\> 2 mg \u002F dl and \u002F or transaminases 5 times the normal limit, not related to ALL.\n* Patients with severe chronic respiratory failure.\n* Renal failure and \u002F or creatininemia\\> 2 mg \u002F dl not related to ALL.\n* Serious neurological disorders, not related to leukemic disease.\n* General condition affected (grades 3 and 4), not attributable to ALL.\n* Uncontrolled infection by HIV, HTLV-1, HBV, HCV.\n* Patient not a candidate for treatment based on the criteria of the treating physician.\n* Pregnant women will have to be evaluated by a multidisciplinary team and an ethics committee.","ALL","18 Years","40 Years",{"count":74,"type":75},100,"ESTIMATED","60 Months","OBSERVATIONAL","This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line pediatric-like protocol in Argentina.",[80],"Acute Lymphoblastic Leukemia, Adult",[82],"Acute Lymphoblastic Leukemia","2024-01-08",{"date":85,"type":86},"2024-01-09","ACTUAL",{"date":88,"type":86},"2021-03-01",{"date":90,"type":75},"2026-12-01",{"name":5,"class":6},2]